User profiles for "author:Sibylle Loibl"

sibylle loibl

Professor for medicine
Verified email at gbg.de
Cited by 86961

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino… - The Lancet, 2014 - thelancet.com
Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …

[HTML][HTML] The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

R Salgado, C Denkert, S Demaria, N Sirtaine… - Annals of oncology, 2015 - Elsevier
Evidence is strengthening for the morphological evaluation of tumor infiltrating lymphocytes
(TILs) in breast cancer. Herein, the concepts for TILs assessment are laid out by pathologists …

[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …

HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …

A Goldhirsch, EP Winer, AS Coates, RD Gelber… - Annals of oncology, 2013 - Elsevier
Abstract The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel
reviewed and endorsed substantial new evidence on aspects of the local and regional …

[PDF][PDF] Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes

G Von Minckwitz, M Untch, JU Blohmer… - J Clin …, 2012 - aula.campuspanamericana.com
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant
Chemotherapy in Various Intrinsic Breast Ca Page 1 Definition and Impact of Pathologic Complete …

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …

J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im… - The Lancet, 2020 - thelancet.com
Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …

[HTML][HTML] Trastuzumab emtansine for residual invasive HER2-positive breast cancer

G Von Minckwitz, CS Huang, MS Mano… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …

[HTML][HTML] Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

F André, E Ciruelos, G Rubovszky… - … England Journal of …, 2019 - Mass Medical Soc
Background PIK3CA mutations occur in approximately 40% of patients with hormone
receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast …

[PDF][PDF] Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer

C Denkert, S Loibl, A Noske, M Roller, BM Muller… - J Clin …, 2010 - researchgate.net
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant
Chemotherapy in Breast Cancer Page 1 Tumor-Associated Lymphocytes As an …

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

C Denkert, G von Minckwitz, S Darb-Esfahani… - The lancet …, 2018 - thelancet.com
Summary Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …